6505-- Denosumab Injections

The solicitation requires offerors to submit a fully approved small‑business subcontracting plan (commercial or individual) in accordance with FAR 52.219‑9 and VAAR 852.219‑70. The plan must detail dollar and percentage goals for each contract period (base and any five‑year options), specify whether it is company‑wide or division‑wide, and include projected subcontract spend, total sales, and any indirect costs. Offerors must justify any goal that is lower than the VA‑suggested target or lower than the prior year’s achievement, describe the methodology used to develop those goals, and list the specific websites, organizations, associations, or events used to identify potential sources. The plan must also address equitable‑opportunity good‑faith efforts for small‑business, veteran‑owned, HUBZone, disadvantaged, and women‑owned firms, providing concrete internal and external actions. In addition, offerors must provide evidence describing the API and final manufacturing processes, identifying which steps constitute a substantial transformation. If an alternate presentation (vial or syringe) of the same strength is marketed after award, it will be added to the contract at the original awarded price. All required provisions (e.g., 52.204‑7, 52.214‑34/35) must be referenced, and the subcontracting plan period must align with the contractor’s fiscal year or cover the entire performance period. Failure to include the essential information outlined in the model template may result in delay or rejection of the offer.

Notice ID

4869b851aba14579b8719c80e0ce2b54

Solicitation Number

36E79726R0018

NAICS Code

325412

Classification Code

6505